191 related articles for article (PubMed ID: 37295817)
1. Zoledronic acid and thymosin α1 elicit antitumor immunity against prostate cancer by enhancing tumor inflammation and cytotoxic T cells.
Wang S; Huang M; Chen M; Sun Z; Jiao Y; Ye G; Pan J; Ye W; Zhao J; Zhang D
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37295817
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of zoledronic acid for the elimination of disseminated tumor cells in a clinically relevant, spontaneously metastatic prostate cancer xenograft model.
Böckelmann LC; Freytag V; Ahlers AK; Maar H; Gosau T; Baranowsky A; Schmitz R; Pantel K; Schumacher U; Haider MT; Lange T
Bone; 2023 Jun; 171():116741. PubMed ID: 36934984
[TBL] [Abstract][Full Text] [Related]
3. [The anti-tumor efforts of thymosin alpha1 on tumor lysate-pulsed dendritic cells in colon cancer in vitro and in vivo].
Ma YL; Zheng Z; Li BD; Xie SJ; Li GX; Yan QH; Cai JH
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Nov; 23(11):1046-9. PubMed ID: 17988589
[TBL] [Abstract][Full Text] [Related]
4. Combination of Gemcitabine and Thymosin alpha 1 exhibit a better anti-tumor effect on nasal natural killer/T-cell lymphoma.
Chen M; Jiang Y; Cai X; Lu X; Chao H
Int Immunopharmacol; 2021 Sep; 98():107829. PubMed ID: 34119916
[TBL] [Abstract][Full Text] [Related]
5. Generation of a novel long-acting thymosin alpha1-Fc fusion protein and its efficacy for the inhibition of breast cancer in vivo.
Shen X; Li Q; Wang F; Bao J; Dai M; Zheng H; Lao X
Biomed Pharmacother; 2018 Dec; 108():610-617. PubMed ID: 30243095
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy.
Lang JM; Wallace M; Becker JT; Eickhoff JC; Buehring B; Binkley N; Staab MJ; Wilding G; Liu G; Malkovsky M; McNeel DG
Clin Genitourin Cancer; 2013 Dec; 11(4):407-15. PubMed ID: 23835291
[TBL] [Abstract][Full Text] [Related]
7. Extracellular Vesicles from
Luo ZW; Xia K; Liu YW; Liu JH; Rao SS; Hu XK; Chen CY; Xu R; Wang ZX; Xie H
Int J Nanomedicine; 2021; 16():2949-2963. PubMed ID: 33907401
[TBL] [Abstract][Full Text] [Related]
8. What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis.
Vale CL; Fisher DJ; White IR; Carpenter JR; Burdett S; Clarke NW; Fizazi K; Gravis G; James ND; Mason MD; Parmar MKB; Rydzewska LH; Sweeney CJ; Spears MR; Sydes MR; Tierney JF
Ann Oncol; 2018 May; 29(5):1249-1257. PubMed ID: 29788164
[TBL] [Abstract][Full Text] [Related]
9. Thymosin alpha 1 - Reimagine its broader applications in the immuno-oncology era.
Mao L
Int Immunopharmacol; 2023 Apr; 117():109952. PubMed ID: 36871535
[TBL] [Abstract][Full Text] [Related]
10. Infiltrating immune cells in prostate cancer tissue after androgen deprivation and radiotherapy.
Erlandsson A; Lundholm M; Watz J; Bergh A; Petrova E; Alamdari F; Helleday T; Davidsson S; Andren O; Tarish F
Int J Immunopathol Pharmacol; 2023; 37():3946320231158025. PubMed ID: 36880147
[TBL] [Abstract][Full Text] [Related]
11. Thymosin α1 and Its Role in Viral Infectious Diseases: The Mechanism and Clinical Application.
Tao N; Xu X; Ying Y; Hu S; Sun Q; Lv G; Gao J
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110771
[TBL] [Abstract][Full Text] [Related]
12. Tumor microenvironment remodeling via targeted depletion of M2-like tumor-associated macrophages for cancer immunotherapy.
Cao Y; Qiao B; Chen Q; Xie Z; Dou X; Xu L; Ran H; Zhang L; Wang Z
Acta Biomater; 2023 Apr; 160():239-251. PubMed ID: 36774974
[TBL] [Abstract][Full Text] [Related]
13. IL-1β Is an Androgen-Responsive Target in Macrophages for Immunotherapy of Prostate Cancer.
Wang D; Cheng C; Chen X; Wang J; Liu K; Jing N; Xu P; Xi X; Sun Y; Ji Z; Zhao H; He Y; Zhang K; Du X; Dong B; Fang Y; Zhang P; Qian X; Xue W; Gao WQ; Zhu HH
Adv Sci (Weinh); 2023 Jun; 10(17):e2206889. PubMed ID: 37092583
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
[TBL] [Abstract][Full Text] [Related]
15. Thymosin α1 promotes the activation of myeloid-derived suppressor cells in a Lewis lung cancer model by upregulating Arginase 1.
Yuan C; Zheng Y; Zhang B; Shao L; Liu Y; Tian T; Gu X; Li X; Fan K
Biochem Biophys Res Commun; 2015 Aug; 464(1):249-55. PubMed ID: 26111447
[TBL] [Abstract][Full Text] [Related]
16. Thymosin Alpha-1 Has no Beneficial Effect on Restoring CD4+ and CD8+ T Lymphocyte Counts in COVID-19 Patients.
Wang Z; Chen J; Zhu C; Liu L; Qi T; Shen Y; Zhang Y; Xu L; Li T; Qian Z; Steinhart CR; Lu H
Front Immunol; 2021; 12():568789. PubMed ID: 34149679
[TBL] [Abstract][Full Text] [Related]
17. Zoledronic acid impairs stromal reactivity by inhibiting M2-macrophages polarization and prostate cancer-associated fibroblasts.
Comito G; Pons Segura C; Taddei ML; Lanciotti M; Serni S; Morandi A; Chiarugi P; Giannoni E
Oncotarget; 2017 Jan; 8(1):118-132. PubMed ID: 27223431
[TBL] [Abstract][Full Text] [Related]
18. Improvement in cognitive dysfunction following blast induced traumatic brain injury by thymosin α1 in rats: Involvement of inhibition of tau phosphorylation at the Thr205 epitope.
Shi QX; Chen B; Nie C; Zhao ZP; Zhang JH; Si SY; Cui SJ; Gu JW
Brain Res; 2020 Nov; 1747():147038. PubMed ID: 32738231
[TBL] [Abstract][Full Text] [Related]
19. Thymosin α1 modulated the immune landscape of COVID-19 patients revealed by single-cell RNA and TCR sequencing.
Bai H; Liang L; Qi X; Xu Y; Liu Y; Ren D; Cai Z; Mao W; Wang X; Qin H; Hu F; Shi B
Int Immunopharmacol; 2023 Nov; 124(Pt B):110983. PubMed ID: 37769533
[TBL] [Abstract][Full Text] [Related]
20. Zoledronic Acid Inhibits the RhoA-mediated Amoeboid Motility of Prostate Cancer Cells.
Pietrovito L; Comito G; Parri M; Giannoni E; Chiarugi P; Taddei ML
Curr Cancer Drug Targets; 2019; 19(10):807-816. PubMed ID: 30648509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
